{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', '3.5.3.', 'Overall Benefit-Risk Conclusions', 'In the ongoing FTIH study, GSK2857916 has shown strong single-agent activity with an', 'ORR of 60% (95% CI: 42.1%, 76.1%) among the 35 participants in Part 2 who received', 'GSK2857916 at 3.4 mg/kg IV, Q3W. The ORR in the 14 participants who failed prior', 'daratumumab treatment was 43% (95% CI: 17.7%, 71.1%), and the PFS in this subgroup', 'was 7.8 months. Although maximum clinical benefit was observed at the 3.4 mg/kg dose', 'level, frequent dose delays and dose reductions were required to manage AEs including', 'thrombocytopenia/platelet count decreased and corneal events.', 'To generate additional safety and efficacy data at a lower dose while providing', 'participants a chance of deriving clinical benefit, two dose levels (2.5 mg/kg Q3W and', '3.4 mg/kg Q3W) will be evaluated in study 205678. Considering the potential benefit to', 'participants as well as the measures being taken to minimize risk, further development of', 'GSK2857916 as monotherapy in participants who failed an anti-CD38 antibody and are', 'refractory to PI and IMiD is warranted. Based on the recognized unmet medical need and', 'limited treatment options available for this population, this Phase II study has been', 'designed to evaluate the efficacy and safety of GSK2857916.', '4.', 'OBJECTIVES AND ENDPOINTS', 'The purpose of this Phase II study is to evaluate the safety and efficacy of GSK2857916', 'in participants with RRMM who have received at least 3 prior lines of anti-myeloma', 'therapy, have failed an anti-CD38 antibody, and are refractory to PI and IMiDs. See', 'Table 6 for the primary, secondary, exploratory, and other objectives, along with the', 'corresponding endpoints.', 'Table 6', 'Objectives and Enppoints for Study 205678 - GSK2857916 in RRMM', 'Participants Previously Treated with an Anti-CD38 Antibody', 'Objectives', 'Enppoints', 'Primary Objective', 'To evaluate the clinical efficacy of 2 doses', 'ORR, defined as the percentage of participants with a confirmed partial', 'of GSK2857916 in participants with', 'response (PR) or better (i.e., PR, very good partial response [VGPR],', 'relapsed/refractory multiple myeloma.', 'complete response [CR] and stringent complete response [sCR]),', 'according to the 2016 International Myeloma Working Group (IMWG)', 'Response Criteria by Independent Review Committee (IRC).', 'Secondary Objectives', 'To further evaluate the clinical measures of', 'ORR, defined as the percentage of participants with a confirmed partial', 'efficacy of GSK2857916 in participants with', 'response (PR) or better, according to the 2016 International Myeloma', 'RRMM', 'Working Group (IMWG) Response Criteria by investigator assessment.', 'Clinical benefit rate (CBR), defined as the percentage of participants', 'with a confirmed minimal response (MR) or better according to the', '2016 International Myeloma Working Group (IMWG) Response', 'Criteria).', 'Duration of response (DoR), defined as: the time from first documented', 'evidence of PR or better until the earliest date of documented disease', 'progression (PD) per IMWG; or death due to PD occurs among', 'participants who achieve an overall response, i.e., confirmed PR or', '41']['2017N330177_04', 'CONFIDENTIAL', '205678', 'Objectives', 'Enppoints', 'better.', 'Time to response, defined as the time between the date of', 'randomization and the first documented evidence of response (PR or', 'better).', 'Progression-free survival, defined as the time from randomization until', 'the earliest date of documented disease progression (PD) per IMWG,', 'or death due to any cause.', 'Time to progression, defined as the time from randomization until the', 'earliest date of documented PD per IMWG, or death due to PD.', 'Overall survival, defined as the time from randomization until death due', 'to any cause.', 'To evaluate the safety of GSK2857916 in', 'The safety profile of GSK2857916 will be evaluated in participants with', 'participants with RRMM.', 'RRMM as assessed through:', 'standard clinical and laboratory tests (hematology and chemistry,', 'physical examination, vital sign measurements, and diagnostic tests)', 'through the collection of adverse events (AEs) and serious adverse', 'events (SAEs)', 'AEs of special interest', 'ocular findings on ophthalmic exam', 'To evaluate the pharmacokinetic profile of', 'Plasma concentrations of GSK2857916 (ADC, total mAb, and cys-', 'GSK2857916', 'mcMMAF)', 'Derived pharmacokinetic parameter values (e.g., AUC, Cmax, tmax,', 't1/2), as data permit.', 'To assess anti-drug antibodies (ADAs)', 'Incidence and titers of ADAs against GSK2857916', 'against GSK2857916', 'Participant self-reported symptomatic', 'Symptomatic adverse effects and related impacts as measured by the', 'adverse effects by evaluation of tolerability', 'PRO-CTCAE, NEI-VFQ-25 and OSDI', 'of GSK2857916', 'To evaluate disease and treatment related', 'Health-related quality-of-life as measured by the EORTC QLQ-C30 and', 'symptoms and impact on function and', 'EORTC QLQ-MY20', 'health-related quality-of-life', 'Exploratory Objectives', 'To explore the relationship between clinical', 'Determine BCMA expression levels and other markers on malignant', 'response and other biologic characteristics', 'cells, serum sBCMA levels, and evaluate the relationship of these', 'including BCMA expression on tumor cells', 'factors to clinical response', 'and sBCMA concentrations', 'To investigate the relationship between', 'Possible relationship between host genetic variation and response to', 'genetic variants in the host and response to', 'GSK2857916', 'GSK2857916', 'To evaluate disease and treatment related', 'Qualitative telephone interview(s)', 'symptoms and impact on function and', 'health-related quality-of-life', 'To explore exposure-response relationships', 'Explore relationships between GSK2857916 exposure (e.g., dose,', 'between GSK2857916 exposure and clinical', 'dose intensity, concentration, Cmax, or AUC) and clinical endpoints', 'endpoints', '(e.g., response, corneal event), if data permit', 'To assess Minimal Residual Disease (MRD)', 'Minimal Residual Disease (MRD) negativity rate, defined as: the', 'in participants who achieve >VGPR or', 'percentage of participants who are MRD negative by Next Generation', 'better', 'Sequencing (NGS).', 'To assess the safety, efficacy,', 'AEs, clinical and laboratory assessments; descriptive analyses of ORR,', 'immunogenicity, and pharmacokinetics of', 'duration of response, time to response, time to progression, overall', 'GSK2857916 in a lyophilized configuration', 'response; incidence and titers against GSK2857916; plasma', '(approximately 25 participants)', 'concentrations of GSK2857916 (ADC, total mAb, and cys-mcMMAF)', '42']\n\n###\n\n", "completion": "END"}